By Michael Greger, M.D., FACLM
October 6, 2026
In the modern landscape of American healthcare, a striking disconnect persists between the clinical potential of preventive medicine and the operational priorities of the insurance industry. While medical research has long identified nutrition as a cornerstone for preventing and even reversing many of the chronic diseases that act as a perpetual drain on national healthcare budgets, the industry’s major payors have remained notably hesitant to aggressively promote plant-based eating. This inertia persists despite data suggesting that even a modest one-percent reduction in excess body fat across the population could yield savings in the tens of billions of dollars annually.
The fundamental question remains: if health insurance companies have a vested interest in reducing the massive expenditures associated with chronic illness, why aren’t they leading the charge toward dietary interventions? To understand this, one must examine the peculiar structural incentives that define the insurance industry. A compelling argument suggests that the insurance sector may, in fact, derive a perverse benefit from high healthcare costs. Because these costs are largely passed on to employers and individual consumers in the form of higher premiums, and because insurers typically retain a fixed percentage of those premiums as profit, there is little financial motivation to drastically lower the overall cost of care.
In this business model, the insurance industry effectively takes a percentage of the total healthcare spend. Consequently, the "pie" of healthcare costs—fueled by the prevalence of chronic, lifestyle-related diseases—creates a larger base upon which insurers can apply their margins. When the population remains chronically ill, the financial volume of the sector remains high, and thus, the insurer’s piece of that pie grows accordingly. As a result, insurers have historically been disincentivized from implementing comprehensive strategies that would fundamentally reduce healthcare costs, as doing so could potentially erode their own bottom line.
This dynamic creates a profound irony in the face of modern medical evidence. Consider, for a moment, the introduction of a hypothetical medication that could successfully treat and reverse heart disease, type 2 diabetes, and hypertension without negative side effects, all while offering the promise of dramatically reduced long-term costs. If such a pharmaceutical miracle were to emerge, the advertising budgets required to promote it would be astronomical, and pharmaceutical companies would surely command a premium price for a product that moves beyond mere symptom management to actual disease resolution.
Yet, this "medication" already exists. It is available to everyone, in virtually unlimited quantities, and at a relatively low cost compared to the lifetime management of chronic conditions. That solution is the use of food as medical treatment, specifically through a diet centered on minimally processed, whole plant foods. Despite the robust scientific literature supporting this approach, the vast majority of the American public remains largely unaware of the extent to which dietary choices can serve as a primary clinical intervention.
One of the most significant barriers to the widespread adoption of plant-based nutrition is a deeply entrenched cultural and clinical belief that once a patient develops a chronic condition like heart disease or type 2 diabetes, the trajectory of the disease is largely fixed. The prevailing medical mindset often assumes that the best possible outcome is the management or maintenance of the condition through lifelong pharmacological intervention, rather than the potential reversal of the underlying pathology. The transformative potential of a whole-food, plant-based diet—which offers a safe, effective, and low-cost alternative to eliminate symptoms—remains largely obscured from the general public. While the pharmaceutical industry spends billions of dollars annually to market new drug therapies, there is no comparable profit motive to promote the consumption of whole plants.
The current political discourse surrounding healthcare in the United States is frequently dominated by the question of "who pays," rather than the more critical inquiry of "what kind of care is best." This focus on fiscal policy over clinical efficacy ignores the mounting evidence that a whole-food, plant-based diet provides the single most effective opportunity to not only slow the growth of healthcare spending but to actually decrease total costs. No single drug, surgical procedure, or insurance reform model can match the systemic impact that a population-wide shift toward plant-based eating could achieve.
Despite these systemic obstacles, there are signs that the medical establishment is beginning to shift its perspective. A review of the evidence published in the journal of Kaiser Permanente, a major integrated healthcare provider, represents a significant step forward. The review concluded that physicians should consider recommending a plant-based diet to all of their patients, with particular emphasis on those suffering from hypertension, diabetes, cardiovascular disease, or obesity.
Moving beyond mere recommendations, organizations like Kaiser Permanente have begun to develop user-friendly resources for both clinicians and patients. These materials, which are now available to the public, provide practical, actionable advice on how to implement a plant-based diet, breaking down the barriers of confusion that often prevent patients from making dietary changes. These guides serve as a template for what the broader insurance industry could accomplish if it were to prioritize public health over the maintenance of existing cost structures.
The potential for a paradigm shift is clear. If insurance companies were to adopt the role of educators, they could fundamentally alter the relationship between patients and their physicians. One could envision a scenario where insurers provide their members with the same type of encouragement that is currently seen in pharmaceutical advertisements. Just as television commercials routinely prompt viewers to "ask your doctor if this drug is right for you," insurers could prompt their members to consult with their physicians about the potential for a plant-based diet to reverse disease and reduce the need for prescription medications.
Of course, if such materials were ever produced, they would require a unique kind of disclosure—a list of "side effects" that would be universally welcomed. Instead of the risks of nausea or dizziness common in drug ads, these materials would highlight the benefits of increased energy, lower blood pressure, improved digestion, and the ability to eat satisfying, unlimited quantities of nutrient-dense food.
Ultimately, the path toward a more sustainable and effective healthcare system involves moving beyond the status quo. By prioritizing the treatment of underlying causes through nutrition, the industry could shift from a model that benefits from illness to one that rewards true health. While the current financial incentives of the insurance industry remain tilted against such a transformation, the growing body of evidence and the emergence of institutional support suggest that the conversation is beginning to change. As patients and providers alike become more informed about the power of plants as medicine, the pressure for the insurance industry to align its practices with the health of its members will only continue to mount. Until then, the challenge to the insurance industry remains the same: to choose between the comfort of an existing, high-cost model and the transformative potential of a healthier, more cost-effective future.